Human Genome Epidemiology Literature Finder
Records 1 - 30 (of 63 Records) |
Query Trace: Breast Neoplasms and CYP3A5[original query] |
---|
Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen. Pharmacogenomics and personalized medicine 2013 6 93-8. Sensorn Insee, Sirachainan Ekaphop, Chamnanphon Montri, Pasomsub Ekawat, Trachu Narumol, Supavilai Porntip, Sukasem Chonlaphat, Pinthong Daraw |
Comparative study of polymorphism frequencies of the CYP2D6, CYP3A5, CYP2C8 and IL-10 genes in Mexican and Spanish women with breast cancer. Pharmacogenomics 2013 Oct 14 (13): 1583-92. Alcazar-González Gregorio Antonio, Calderón-Garcidueñas Ana Laura, Garza-Rodríguez María Lourdes, Rubio-Hernández Gabriela, Escorza-Treviño Sergio, Olano-Martin Estibaliz, Cerda-Flores Ricardo Martín, Castruita-Avila Ana Lilia, González-Guerrero Juan Francisco, le Brun Stéphane, Simon-Buela Laureano, Barrera-Saldaña Hugo Alber |
Assessment of clinical outcomes in breast cancer patients treated with taxanes: multi-analytical approach. Gene 2014 Jun 543 (1): 69-75. Tulsyan Sonam, Chaturvedi Pankaj, Singh Abhishek Kumar, Agarwal Gaurav, Lal Punita, Agrawal Sushma, Mittal Rama Devi, Mittal Balr |
Significant role of CYP450 genetic variants in cyclophosphamide based breast cancer treatment outcomes: a multi-analytical strategy. Clinica chimica acta; international journal of clinical chemistry 2014 Jul 434 21-8. Tulsyan Sonam, Agarwal Gaurav, Lal Punita, Mittal Balr |
Transformation of alkylating regimen of thiotepa into tepa determines the disease progression through GSTP1 gene polymorphism for metastatic breast cancer patients receiving thiotepa containing salvage chemotherapy. International journal of clinical pharmacology and therapeutics 2015 Sep . Zhou Xinna, Wang Xiaoli, Song Qingkun, Yang Huabing, Zhu Xishan, Yu Jing, Song Guohong, Di Lijun, Ren Jun, Shao Hong, Lyerly Herbert K |
Generalized Multifactor Dimensionality Reduction (GMDR) Analysis of Drug-Metabolizing Enzyme-Encoding Gene Polymorphisms may Predict Treatment Outcomes in Indian Breast Cancer Patients. World journal of surgery 2015 Oct . Agarwal Gaurav, Tulsyan Sonam, Lal Punita, Mittal Balr |
Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment. Breast cancer (Dove Medical Press) 2016 8 149-55. Charoenchokthavee Wanaporn, Panomvana Duangchit, Sriuranpong Virote, Areepium Nuttha |
Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1. Journal of clinical pharmacology 2016 May . Powers Jennifer L, Buys Saundra S, Fletcher Deborah, Melis Roberta, Johnson-Davis Kamisha, Lyon Elaine, Malmberg Elisabeth M, McMillin Gwendolyn |
ABCB1 and ABCC2 and the risk of distant metastasis in Thai breast cancer patients treated with tamoxifen. OncoTargets and therapy 2016 9 2121-9. Sensorn Insee, Sukasem Chonlaphat, Sirachainan Ekaphop, Chamnanphon Montri, Pasomsub Ekawat, Trachu Narumol, Supavilai Porntip, Pinthong Darawan, Wongwaisayawan Sansan |
Drug-related genetic polymorphisms affecting severe chemotherapy-induced neutropenia in breast cancer patients: A hospital-based observational study. Medicine 2016 Nov 95 (44): e5151. Tsuji Daiki, Ikeda Midori, Yamamoto Keisuke, Nakamori Harumi, Kim Yong-Il, Kawasaki Yohei, Otake Aki, Yokoi Mari, Inoue Kazuyuki, Hirai Keita, Nakamichi Hidenori, Tokou Umi, Shiokawa Mitsuru, Itoh Kunihi |
Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism. European journal of clinical pharmacology 2017 8 73 (12): 1589-1598. Sanchez Spitman A B, Moes D J A R, Gelderblom H, Dezentje V O, Swen J J, Guchelaar H |
Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes. Anticancer research 2017 05 37 (5): 2633-2639. Angelini Silvia, Botticelli Andrea, Onesti Concetta Elisa, Giusti Raffaele, Sini Valentina, Durante Valeria, Strigari Lidia, Gentile Giovanna, Cerbelli Bruna, Pellegrini Patrizia, Sgroi Valentina, Occhipinti Mario, DI Pietro Francesca Romana, Rossi Alessandro, Simmaco Maurizio, Mazzuca Federica, Marchetti Pao |
Effects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients. Breast cancer (Dove Medical Press) 2017 9 249-256. Charoenchokthavee Wanaporn, Areepium Nutthada, Panomvana Duangchit, Sriuranpong Viro |
The influence of CYP3A5*3 and BCRPC421A genetic polymorphisms on the pharmacokinetics of felodipine in healthy Chinese volunteers. Journal of clinical pharmacy and therapeutics 2017 Feb . Xiang Q, Li C, Zhao X, Cui Y |
Pharmacogenetic impact of docetaxel on neoadjuvant treatment of breast cancer patients. Pharmacogenomics 2018 Sep . Sim Sarah, Bergh Jonas, Hellström Mats, Hatschek Thomas, Xie Hanji |
Detection of Cytochrome P450 Polymorphisms in Breast Cancer Patients May Impact on Tamoxifen Therapy. Asian Pacific journal of cancer prevention : APJCP 2018 Feb 19 (2): 343-350. Thota Kanakaiah, Prasad K, Basaveswara Rao Mandava |
Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care. Journal of thrombosis and thrombolysis 2019 Sep . Gulilat Markus, Keller Denise, Linton Bradley, Pananos A Demetri, Lizotte Daniel, Dresser George K, Alfonsi Jeffrey, Tirona Rommel G, Kim Richard B, Schwarz Ute |
CYP2D6 Genotype Predicts Plasma Concentrations of Tamoxifen Metabolites in Ethiopian Breast Cancer Patients. Cancers 2019 9 11 (9): . Ahmed Jemal Hussien, Makonnen Eyasu, Fotoohi Alan, Aseffa Abraham, Howe Rawleigh, Aklillu Ele |
Genetic Variation in Steroid and Xenobiotic Metabolizing Pathways and Enterolactone Excretion Before and After Flaxseed Intervention in African American and European American Women. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2019 Feb 28 (2): 265-274. Chang Huiru, Yao Song, Tritchler David, Hullar Meredith A, Lampe Johanna W, Thompson Lilian U, McCann Susan |
Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation. Basic & clinical pharmacology & toxicology 2020 Sep . Nakagawa Junichi, Kinjo Takahiko, Iizuka Mei, Ueno Kayo, Tomita Hirofumi, Niioka Takeno |
ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone. Progress in neuro-psychopharmacology & biological psychiatry 2020 Jul 110042. Ganoci Lana, Trkulja Vladimir, Živkovi? Maja, Božina Tamara, Šagud Marina, Lovri? Mila, Božina Na |
Representation of CYP3A4, CYP3A5 and UGT1A4 Polymorphisms within Croatian Breast Cancer Patients' Population. International journal of environmental research and public health 2020 May 17 (10): . Bojanic Kristina, Kuna Lucija, Bilic Curcic Ines, Wagner Jasenka, Smolic Robert, Kralik Kristina, Kizivat Tomislav, Ivanac Gordana, Vcev Aleksandar, Wu George Y, Smolic Marti |
Population Pharmacokinetic, Pharmacogenetic, and Pharmacodynamic Analysis of Cyclophosphamide in Ethiopian Breast Cancer Patients. Frontiers in pharmacology 2020 5 11 406. Ahmed Jemal Hussien, Makonnen Eyasu, Bisaso Ronald Kuteesa, Mukonzo Jackson Kijumba, Fotoohi Alan, Aseffa Abraham, Howe Rawleigh, Hassan Moustapha, Aklillu Ele |
Predictive pharmacogenetic biomarkers for breast cancer recurrence prevention by simvastatin. Acta oncologica (Stockholm, Sweden) 2020 5 59 (9): 1009-1015. Ahern Thomas P, Damkier Per, Feddersen Søren, Kjærsgaard Anders, Lash Timothy L, Hamilton-Dutoit Stephen, Lythjohan Cathrine Bredal, Ejlertsen Bent, Christiansen Peer M, Cronin-Fenton Deirdre |
Preliminary Pharmacogenomic-Based Predictive Models of Tamoxifen Response in Hormone-dependent Chilean Breast Cancer Patients. Frontiers in pharmacology 2021 12 12 661443. Miranda Carla, Galleguillos Macarena, Torres Roberto, Tardón Karla, Cáceres Dante D, Lee Kuen, Redal María A, Varela Nelson M, Quiñones Luis |
An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer. Frontiers in pharmacology 2022 8 13 897951. Roncato Rossana, Gerratana Lorenzo, Palmero Lorenza, Gagno Sara, Poetto Ariana Soledad, Peruzzi Elena, Zanchetta Martina, Posocco Bianca, De Mattia Elena, Canil Giovanni, Alberti Martina, Orleni Marco, Toffoli Giuseppe, Puglisi Fabio, Cecchin Eri |
Impacts of pregnane X receptor and cytochrome P450 oxidoreductase gene polymorphisms on trough concentrations of apixaban in patients with non-valvular atrial fibrillation. European journal of clinical pharmacology 2022 11 79 (1): 127-135. Nakagawa Junichi, Kinjo Takahiko, Aiuchi Naoya, Ueno Kayo, Tomita Hirofumi, Niioka Takeno |
ABCG2 Gene Polymorphisms May Affect the Bleeding Risk in Patients on Apixaban and Rivaroxaban. Drug design, development and therapy 2023 8 17 2513-2522. Hamin Kim, Tae-Jin Song, Jeong Yee, Dong-Hyeok Kim, Junbeom Park, Hye Sun Gw |
Predictive modeling of adverse drug reactions to tamoxifen therapy for breast cancer on base of pharmacogenomic testing. Drug metabolism and personalized therapy 2023 7 . Ekaterina Olegovna Golubenko, Marina Ivanovna Savelyeva, Zhannet Alimovna Sozaeva, Vera Vyacheslavovna Korennaya, Irina Vladimirovna Poddubnaya, Timur Tejmurazovich Valiev, Svetlana Nikolaevna Kondratenko, Mikhail Vitalyevich Ily |
Cytochrome P450 oxidoreductase, POR, associated with severe paclitaxel-induced peripheral neuropathy in patients of European ancestry from ECOG-ACRIN E5103. Clinical cancer research : an official journal of the American Association for Cancer Research 2023 5 . Fei Shen, Guanglong Jiang, Santosh Philips, Laura Gardner, Gloria Xue, Erica Cantor, Reynold C Ly, Wilberforce Osei, Xi Wu, Chau Dang, Donald Northfelt, Todd Skaar, Kathy D Miller, George W Sledge, Bryan P Schneid |
- Page last reviewed:Feb 1, 2023
- Page last updated:Sep 18, 2023
- Content source: